1. Home
  2. DVA vs CRS Comparison

DVA vs CRS Comparison

Compare DVA & CRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVA
  • CRS
  • Stock Information
  • Founded
  • DVA 1994
  • CRS 1910
  • Country
  • DVA United States
  • CRS United States
  • Employees
  • DVA N/A
  • CRS N/A
  • Industry
  • DVA Misc Health and Biotechnology Services
  • CRS Steel/Iron Ore
  • Sector
  • DVA Health Care
  • CRS Industrials
  • Exchange
  • DVA Nasdaq
  • CRS Nasdaq
  • Market Cap
  • DVA 10.9B
  • CRS 9.4B
  • IPO Year
  • DVA 1995
  • CRS N/A
  • Fundamental
  • Price
  • DVA $136.18
  • CRS $234.56
  • Analyst Decision
  • DVA Hold
  • CRS Buy
  • Analyst Count
  • DVA 4
  • CRS 6
  • Target Price
  • DVA $157.00
  • CRS $157.17
  • AVG Volume (30 Days)
  • DVA 828.5K
  • CRS 834.3K
  • Earning Date
  • DVA 05-12-2025
  • CRS 07-24-2025
  • Dividend Yield
  • DVA N/A
  • CRS 0.34%
  • EPS Growth
  • DVA 14.90
  • CRS 168.78
  • EPS
  • DVA 10.11
  • CRS 7.05
  • Revenue
  • DVA $12,968,524,000.00
  • CRS $2,920,100,000.00
  • Revenue This Year
  • DVA $6.00
  • CRS $7.15
  • Revenue Next Year
  • DVA $3.66
  • CRS $9.47
  • P/E Ratio
  • DVA $13.48
  • CRS $33.35
  • Revenue Growth
  • DVA 5.11
  • CRS 7.38
  • 52 Week Low
  • DVA $131.76
  • CRS $95.17
  • 52 Week High
  • DVA $179.60
  • CRS $238.94
  • Technical
  • Relative Strength Index (RSI)
  • DVA 37.73
  • CRS 66.00
  • Support Level
  • DVA $136.50
  • CRS $219.58
  • Resistance Level
  • DVA $140.42
  • CRS $238.94
  • Average True Range (ATR)
  • DVA 3.66
  • CRS 7.71
  • MACD
  • DVA -0.59
  • CRS -0.50
  • Stochastic Oscillator
  • DVA 11.71
  • CRS 83.34

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

About CRS Carpenter Technology Corporation

Carpenter Technology Corp supplies specialty metals to a variety of end markets, including aerospace and defense, industrial machinery and consumer durables, medical, and energy, among others. The company's reportable segments include; Specialty Alloys Operations and Performance Engineered Products. It generates maximum revenue from the Specialty Alloys Operations segment. The SAO segment is comprised of the company's alloy and stainless steel manufacturing operations. This includes operations performed at mills predominantly in Reading and Latrobe, Pennsylvania, and surrounding areas as well as South Carolina and Alabama. Geographically, the company derives its maximum revenue from the United States and the rest from Europe, Asia Pacific, Mexico, Canada, and other regions.

Share on Social Networks: